EH
CRSP icon

Equitable Holdings’s CRISPR Therapeutics CRSP Stock Holding History

Equitable Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$891K Buy
16,341
+4,050
+33% +$213K 0.01% 1049
2026
Q1 		$608K Buy
12,291
+6,527
+113% +$344K ﹤0.01% 1171
2025
Q4 		$302K Sell
5,764
-262
-4% -$15.7K ﹤0.01% 1327
2025
Q3 		$391K Buy
6,026
+1,115
+23% +$64K ﹤0.01% 1161
2025
Q2 		$239K Buy
+4,911
New +$190K ﹤0.01% 1302
2024
Q4 		– Sell
-4,398
Closed -$207K – 1283
2024
Q3 		$207K Buy
+4,398
New +$223K ﹤0.01% 1177
2024
Q2 		– Sell
-4,853
Closed -$331K – 1219
2024
Q1 		$331K Buy
4,853
+1,162
+31% +$83.2K ﹤0.01% 931
2023
Q4 		$231K Buy
+3,691
New +$204K ﹤0.01% 1025

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Equitable Holdings's CRSP Position: Q2 2026 in Review

Equitable Holdings increased its CRISPR Therapeutics (CRSP) stake by 33% in Q2 2026, buying an estimated $213K and bringing the position to 16,341 shares worth $891K. The position accounts for 0.01% of the portfolio, ranked #1049.

Equitable Holdings first reported a position in CRSP in Q4 2023 and has held it in 8 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Equitable Holdings held 16,341 shares of CRISPR Therapeutics worth $891K as of Q2 2026.
  • Equitable Holdings bought 4,050 CRISPR Therapeutics shares in Q2 2026, an estimated $213K.
  • CRISPR Therapeutics made up 0.01% of Equitable Holdings's portfolio in Q2 2026, its #1049 holding.
  • Equitable Holdings first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Equitable Holdings's 13F filing for Q2 2026, filed 17 Aug 2026.